Arpida AG has announced plans to reduce its workforce by three-quarters and stop two clinical-stage drug programmes following an unexpected negative opinion on its candidate antibiotic for skin infections by an advisory committee of the US Food and Drug Administration. The restructuring measures were announced on 16 December 2008.
